Company intelligence / Profile preview

Corsair Pharma

Sunnyvale, California, United Statescorsairpharma.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Corsair Pharma has successfully completed preclinical programs for its treprostinil prodrug transdermal patch and is advancing to clinical trials with recent Series B funding. The company aims to provide continuous and consistent blood levels of treprostinil comparable to an infusion pump through its proprietary transdermal delivery system.

Therapeutic areas: PulmonologyCardiovascular
Modalities: Prodrugstransdermal patch delivery
Industry: Biotech

Drug pipeline

1 asset

TRX-248

Unknown

Partnerships

United Therapeutics (market leader in PAH therapies)

Beyond the preview

Go deeper on Corsair Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corsair Pharma.

Explore the full profile